The Persistent Challenge of Leukemia Relapse in CAR-T Therapy

Leukemia, a group of blood cancers characterized by the rapid proliferation of abnormal white blood cells, remains a significant health burden in China. Recent data indicate approximately 43,000 new acute leukemia cases annually, with around 55,000 deaths reported in 2020, though mortality rates have been declining due to advances in treatment. Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a revolutionary immunotherapy where a patient's own T cells—immune cells responsible for targeting and destroying infected or cancerous cells—are extracted, genetically engineered in a lab to express chimeric antigen receptors (CARs) that recognize specific cancer surface markers like CD19 on B-cell acute lymphoblastic leukemia (B-ALL) cells, expanded, and reinfused to attack the malignancy.

Despite remarkable initial response rates exceeding 80% in B-ALL, over 50% of patients experience relapse, primarily due to antigen escape: leukemia cells downregulate or lose the targeted antigen (e.g., CD19), rendering CAR-T cells ineffective. Traditional countermeasures involve redesigning CAR-T cells to target new antigens, a process that is time-intensive, costly, and technically demanding. This gap has spurred Chinese researchers to innovate solutions that enhance existing CAR-T without genetic modifications.

Breakthrough: The FACE Molecular Bridge Emerges

Researchers from the Institute of Process Engineering (IPE) at the Chinese Academy of Sciences (CAS) have pioneered Ferritin Aggregation Cell Engager (FACE), a biomimetic 'molecular bridge' that dramatically boosts CAR-T efficacy against refractory leukemias. Published in the prestigious journal Cell on March 9, 2026 (DOI: 10.1016/j.cell.2026.02.005), the study titled 'Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias' demonstrates FACE's ability to bridge CAR-T cells to leukemia cells even when antigens are scarce.

FACE leverages ferritin, an endogenous protein that naturally binds transferrin receptor 1 (CD71, also known as TfR1), which is highly expressed on proliferating leukemia cells and activated CAR-T cells. By inducing controlled self-assembly of ferritin with FDA-approved polymers, FACE forms nanoscale aggregates that act as a physical and functional linker, enhancing 'avidity'—the overall binding strength between effector and target cells.

The Role of CD71: A Universal Target in Proliferating Cells

CD71, the cellular receptor for iron-transport protein transferrin, is upregulated in rapidly dividing cells to meet heightened iron demands for DNA synthesis and metabolism. Studies confirm CD71's consistent high expression across leukemia subtypes and stages, including in antigen-low or escaped cells under therapeutic pressure. Unlike lineage-specific antigens like CD19, CD71's ubiquity on both malignant blasts and therapeutic T cells makes it ideal for bridging without off-target effects on normal tissues, where expression is low.

This strategic choice circumvents antigen heterogeneity, a major hurdle in solid tumors and relapsed blood cancers alike. Chinese research highlights CD71 as a prognostic marker in acute myeloid leukemia (AML), correlating with poor outcomes due to its association with aggressive proliferation.

Step-by-Step Mechanism of FACE-Enhanced CAR-T Therapy

1. Preparation Phase: CAR-T cells (engineered against CD19) are co-incubated with FACE aggregates. Ferritin subunits bind CD71 on CAR-T surfaces, securely anchoring one end of the bridge.
2. Infusion: FACE-armed CAR-T cells are reinfused into the patient.
3. Targeting and Bridging: In the bone marrow or bloodstream, the free ferritin end of FACE recognizes CD71 on leukemia cells, drawing them into close proximity with CAR-T cells.
4. Avidity Boost and Lysis: Proximity amplifies CAR-CD19 interactions (even at low density), activating T-cell signaling cascades, cytokine release, and perforin/granzyme-mediated tumor cell death.
5. Drug Delivery (FACED Variant): Optional loading of chemotherapeutics into ferritin nanocages targets residual antigen-negative clones.

This plug-and-play integration requires no workflow changes, positioning FACE as a universal enhancer.

Photo by Pontus Wellgraf on Unsplash

Experimental Triumphs: From In Vitro to In Vivo Validation

In patient-derived xenograft (PDX) mouse models of relapsed B-ALL with normal CD19, FACE-CAR-T achieved equivalent tumor clearance using just one-fifth the cell dose of standard CAR-T, minimizing cytokine release syndrome (CRS) risks. Critically, in antigen-low (<10% CD19) models—mimicking relapse—standard therapy failed, but FACE-CAR-T eradicated leukemia, yielding 100% survival.

Analysis of over 100 patient samples from collaborators confirmed broad efficacy across leukemia types. FACED further eliminated antigen-negative subpopulations in high-burden models (up to 40% leukemia infiltration). An AI predictive model forecasts FACE responsiveness, aiding personalized therapy.

Pioneering Team: CAS Leadership and University Collaborations

Lead investigators Prof. Wei Wei and Prof. Ma Guanghui from CAS-IPE orchestrated this feat, drawing clinical insights from Zhujiang Hospital (Southern Medical University) and the Institute of Hematology & Blood Diseases Hospital (Peking Union Medical College, Chinese Academy of Medical Sciences).Explore research jobs at these institutions fueling China's biotech revolution.

"FACE is a tiny bridge or strong glue," Wei explained, emphasizing its seamless fit into manufacturing.

Chinese Universities Powering Immunotherapy Innovation

China leads globally in CAR-T trials, with over 100 ongoing, many university-led. Peking Union Medical College pioneered CNCT19 (first domestic CAR-T approval for refractory leukemia), while Southern Medical University's Zhujiang Hospital advances multi-target CARs. Institutions like Zhejiang University report high remission rates, countering antigen escape via bispecific designs. For aspiring researchers, opportunities abound in China's higher ed jobs.

Advantages Revolutionizing Refractory Leukemia Treatment

• Dose Reduction: 80% fewer cells needed, cutting costs and toxicity.
• Antigen Independence: Effective vs. escape variants via CD71 bridging.
• Safety: Lower CRS incidence; ferritin biocompatibility.
• Scalability: Non-genetic, rapid production.
• Versatility: Applicable to diverse leukemias; drug-loading potential.

Peer reviewers hailed it as 'highly relevant' for hematologic malignancies.

Photo by Hoi An and Da Nang Photographer on Unsplash

Future Horizons: Clinical Translation and Global Impact

With preclinical success, teams plan expanded PDX testing and AI optimization. China's NMPA has approved multiple CAR-Ts (e.g., Carteyva for MCL), accelerating FACE's path. Long-term, it could extend to solid tumors. For students, career advice in immunotherapy research is key. Check professor ratings at leading Chinese unis.

China's Leadership in CAR-T: A Higher Ed Success Story

Universities drive 70% of China's CAR-T innovations, from dual-target designs at Tongji Medical College to NK-CAR at China Medical University. FACE exemplifies collaborative academia-industry pushes toward self-reliance. Explore postdoc positions or university jobs in oncology.

This advancement not only promises better outcomes for China's leukemia patients but positions its universities as global immunotherapy hubs.